Whitaker Cardiovascular Institute and Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Section of Pulmonary and Critical Care, Department of Medicine, Boston University School of Medicine, and Boston Medical Center, Boston, MA, USA.
Sci Rep. 2022 Apr 4;12(1):5583. doi: 10.1038/s41598-022-09343-1.
Neutrophil-mediated secondary tissue injury underlies acute respiratory distress syndrome (ARDS) and progression to multi-organ-failure (MOF) and death, processes linked to COVID-19-ARDS. This secondary tissue injury arises from dysregulated neutrophils and neutrophil extracellular traps (NETs) intended to kill pathogens, but instead cause cell-injury. Insufficiency of pleiotropic therapeutic approaches delineate the need for inhibitors of dysregulated neutrophil-subset(s) that induce subset-specific apoptosis critical for neutrophil function-shutdown. We hypothesized that neutrophils expressing the pro-survival dual endothelin-1/VEGF-signal peptide receptor, DEspR, are apoptosis-resistant like DEspR+ cancer-cells, hence comprise a consequential pathogenic neutrophil-subset in ARDS and COVID-19-ARDS. Here, we report the significant association of increased peripheral DEspR+CD11b+ neutrophil-counts with severity and mortality in ARDS and COVID-19-ARDS, and intravascular NET-formation, in contrast to DEspR[-] neutrophils. We detect DEspR+ neutrophils and monocytes in lung tissue patients in ARDS and COVID-19-ARDS, and increased neutrophil RNA-levels of DEspR ligands and modulators in COVID-19-ARDS scRNA-seq data-files. Unlike DEspR[-] neutrophils, DEspR+CD11b+ neutrophils exhibit delayed apoptosis, which is blocked by humanized anti-DEspR-IgG4 antibody, hu6g8, in ex vivo assays. Ex vivo live-cell imaging of Rhesus-derived DEspR+CD11b+ neutrophils showed hu6g8 target-engagement, internalization, and induction of apoptosis. Altogether, data identify DEspR+CD11b+ neutrophils as a targetable 'rogue' neutrophil-subset associated with severity and mortality in ARDS and COVID-19-ARDS.
中性粒细胞介导的继发性组织损伤是急性呼吸窘迫综合征 (ARDS) 的基础,并导致多器官衰竭 (MOF) 和死亡,这与 COVID-19-ARDS 有关。这种继发性组织损伤源于失调的中性粒细胞和中性粒细胞细胞外陷阱 (NETs),这些陷阱旨在杀死病原体,但反而导致细胞损伤。多效性治疗方法的不足说明了需要抑制失调的中性粒细胞亚群,这些亚群诱导关键的中性粒细胞功能关闭的亚群特异性细胞凋亡。我们假设表达生存素双内皮素-1/VEGF-信号肽受体 (DEspR) 的中性粒细胞与表达 DEspR 的癌症细胞一样具有抗凋亡性,因此在 ARDS 和 COVID-19-ARDS 中构成了一个重要的致病中性粒细胞亚群。在这里,我们报告了外周血中表达 DEspR 的 CD11b+中性粒细胞计数的增加与 ARDS 和 COVID-19-ARDS 的严重程度和死亡率以及血管内 NET 形成显著相关,而与 DEspR[-]中性粒细胞相反。我们在 ARDS 和 COVID-19-ARDS 患者的肺组织中检测到 DEspR+中性粒细胞和单核细胞,并且在 COVID-19-ARDS 的 scRNA-seq 数据文件中检测到中性粒细胞 DEspR 配体和调节剂的 RNA 水平增加。与 DEspR[-]中性粒细胞不同,DEspR+CD11b+中性粒细胞表现出延迟的凋亡,而在体外实验中,人源化抗 DEspR-IgG4 抗体 hu6g8 可阻断这种凋亡。恒河猴来源的 DEspR+CD11b+中性粒细胞的体外活细胞成像显示 hu6g8 可与靶标结合、内化并诱导凋亡。总之,这些数据确定 DEspR+CD11b+中性粒细胞是一个可靶向的“流氓”中性粒细胞亚群,与 ARDS 和 COVID-19-ARDS 的严重程度和死亡率相关。